Fig. 6.

EphA2 is correlated with breast tumor progression. (a) IHC staining analysis was performed to detect the expression of EphA2 in breast cancer tissue microarray. Left, representative staining for EphA2; right, the relative expression of EphA2 in different breast cancer stages (normal, malignant and metastatic). Scale bar, 20 μm. (b) Western blot analysis was performed to detect indicated protein expression in 4T1 primary tumor tissue. (c) MDA231 cells were treated with WW437 and an EphA2 inhibitor either alone or in combination. The cell viability was tested by MTS assay (48 h). (d) MDA231 cells were treated with WW437 and an EphA2 inhibitor either alone or in combination. The cell migration was tested by wound-healing migration assay. The bars indicate the mean ± SD.